The main interest in routine practice is to consider LB as an option for the identification and monitoring of EGFR mutations in late stage NSCLC, given the good rates of concordance with matched tissue biopsies when robust mutation testing tools are used. This evidence concerns the gene EGFR and non-small cell lung carcinoma.